

# Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

**Status:** RECRUITING

## Eligibility Criteria

**Age:** 18 years and over

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

### Inclusion Criteria:

->18 years of age \* Advanced liver disease \* Able to give written, informed consent \* Alcohol as a cause of advanced liver disease \* Continued sustained drinking \* Having previously declined a referral to traditional AUD therapy services or having failed such treatments

### Exclusion Criteria:

\* Lack of sustained drinking \* Recent or current alcoholic hepatitis \* Alcohol withdrawal symptoms \* Clinically significant use of illicit drugs \* Uncontrolled mood disorders or primary psychotic conditions \* MELD score<17 \* Unclear diagnosis of chronic liver disease \* Current hepatic encephalopathy on lactulose and/or rifaximin \* WBC count<1000 \* Non-elective hospitalization within last month \* on dialysis \* known untreated, in-situ luminal GI cancers \* chronic intrinsic GI diseases (ulcerative colitis, Crohn's disease or microscopic colitis, eosinophilic gastroenteritis and celiac disease) \* Dysphagia within 2 weeks \* History of aspiration, gastroparesis, intestinal obstruction \* Ongoing absorbable antibiotic use \* Severe anaphylactic food allergy \* allergy to ingredients Generally Recognized As Safe in the G3 capsules (glycerol, sodium chloride, hypromellose, gellan gum, titanium dioxide, theobroma oil) \* Adverse event attributable to prior IMT \* ASA Class IV or V \* Pregnant or nursing patients \* acute illness or fever on the day of planned FMT \* Immunosuppression \* Other conditions which make patients are poor candidate for this study per investigator judgement

## Conditions & Interventions

### Interventions:

DRUG: Intestinal Microbiota Transplant (IMT) Capsules, DRUG: Placebo Capsules

### Conditions:

Liver Disease, Alcohol-Related, Cirrhosis, Alcohol Use Disorder

### Keywords:

Intestinal Microbiota Transplant, Alcohol Use Disorder, Cirrhosis, Chronic Liver Disease

## More Information

**Contact(s):** Jasmohan S Bajaj, MD - jasmohan.bajaj@vcuhealth.org

**Principal Investigator:**

**Phase:** PHASE1

**IRB**

**Number:**

**System ID:** NCT05548452

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact [ctrrecruit@vcu.edu](mailto:ctrrecruit@vcu.edu) if you have questions or need assistance.